Holen Sie sich die Stockscreener-App
9.56
0.42%
-0.04
Handel nachbörslich:
9.54
-0.02
-0.21%
Schlusskurs vom Vortag:
$9.60
Offen:
$9.54
24-Stunden-Volumen:
3.47M
Relative Volume:
0.88
Marktkapitalisierung:
$2.49B
Einnahmen:
$6.29B
Nettoeinkommen (Verlust:
$750.00M
KGV:
3.3194
EPS:
2.88
Netto-Cashflow:
$586.00M
1W Leistung:
-9.81%
1M Leistung:
-10.23%
6M Leistung:
-15.40%
1J Leistung:
-47.18%
1-Tages-Spanne:
$9.405
$9.66
1-Wochen-Bereich:
$9.405
$10.77
52-Wochen-Spanne:
$8.01
$19.05
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Vergleichen Sie OGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.56 | 2.50B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
812.35 | 734.56B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.85 | 459.75B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
229.13 | 406.84B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.26 | 249.96B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
84.70 | 214.06B | 63.43B | 16.42B | 14.72B | 6.4861 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
UNFPA Thailand Joins Organon Thailand to Empower Women to Shape Their Own Future - Khaosod English
What analysts say about Organon Co stockVolume Profile Analysis & Next-Level Stock Intelligence, Now Free - earlytimes.in
Are OGN’s Debt Reduction Efforts Enough to Shift Market Perception on Long-Term Growth? - simplywall.st
DexCom, Masimo, Integer Holdings, The Pennant Group, and Organon Stocks Trade Down, What You Need To Know - The Globe and Mail
Organon & Co.'s (OGN) "Sell (D+)" Rating Reiterated at Weiss Ratings - MarketBeat
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN
Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks - The Globe and Mail
Is There Now Opportunity in Organon Stock After Recent Double Digit Drop in 2025? - Yahoo
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
Is Organon a Hidden Bargain After Shares Drop Nearly 40% in 2024? - simplywall.st
Organon (OGN) Stock Slides as Market Rises: Facts to Know Before You Trade - sharewise.com
Will Organon (OGN) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
Is Organon (NYSE:OGN) A Risky Investment? - 富途牛牛
Is Organon Co a good long term investmentInterest Rate Changes & Advanced Stock Screening Tools - earlytimes.in
Public Employees Retirement System of Ohio Sells 23,948 Shares of Organon & Co. $OGN - MarketBeat
3 Reasons To Avoid OGN And 1 Stock To Buy Instead - Barchart.com
3 Reasons to Avoid OGN and 1 Stock to Buy Instead - The Globe and Mail
Organon (NYSE:OGN) Has No Shortage Of Debt - 富途牛牛
Organon & Co trades in the red for seven straight sessions - MSN
Organon & Co. (NYSE:OGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Co. (7XP) stock good for long term investingJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com
Organon & Co. $OGN Shares Acquired by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat
Organon & Co. $OGN Shares Purchased by State of Alaska Department of Revenue - MarketBeat
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know - Yahoo
Organon (OGN) Shares Skyrocket, What You Need To Know - MSN
Co. (7XP) stock in 2025Quarterly Profit Review & Community Driven Trade Alerts - newser.com
Organon & Co. $OGN Stake Lessened by Sound Income Strategies LLC - MarketBeat
Dakota Wealth Management Has $151,000 Stock Position in Organon & Co. $OGN - MarketBeat
Co. (7XP) stock considered safe havenPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Organon (OGN) Outperforms Broader Market: What You Need to Know - sharewise.com
Sterneck Capital Management LLC Makes New Investment in Organon & Co. $OGN - MarketBeat
Register Financial Advisors LLC Sells 30,706 Shares of Organon & Co. $OGN - MarketBeat
Organon partners across Asia Pacific to push equitable access to contraception ahead of World Contraception Day - MediaBrief
Here's Why Organon (OGN) Fell More Than Broader Market - sharewise.com
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - sharewise.com
Organon & Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Wedmont Private Capital Acquires 106,561 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN): Examining Valuation Following European Approval of Denosumab Biosimilars - simplywall.st
Organon announces departure of chief commercial officer - MSN
Gilman Hill Asset Management LLC Sells 443,231 Shares of Organon & Co. $OGN - MarketBeat
Triumph Capital Management Acquires 47,127 Shares of Organon & Co. $OGN - MarketBeat
Organon (OGN) Stock Dips While Market Gains: Key Facts - sharewise.com
Organon gets EU approval for Prolia and Xgeva biosimilars - MSN
Douglas Lane & Associates LLC Raises Holdings in Organon & Co. $OGN - MarketBeat
Organon Q2 Preview: What to expect? - MSN
Ocugen gets EU approval for Prolia and Xgeva biosimilars - MSN
Organon (OGN) Gains EU Approval for Denosumab Biosimilars - GuruFocus
Organon gets EU approval for Prolia and Xgeva biosimilars (OGN:NYSE) - Seeking Alpha
Organon, Shanghai Henlius: EC approves marketing for Bildyos, Bilprevda - TipRanks
(denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively - Business Wire
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):